歌礼制药有限公司（股份代号：01672）于2025年12月3日公布翌日披露报表，显示公司于当日透过香港联合交易所有限公司回购1,306,000股普通股，每股买入价格区间为每股港币11.68元至12.48元，涉资总额约港币15,927,540元。该批回购股份占公司现有已发行股本约0.1317%。
根据公告，回购涉及的股份尚未注销，公司截至2025年12月3日的已发行股份及库藏股数量分别维持在991,974,320股及6,984,210股，总计998,958,530股。公告提及，公司此前于2025年5月22日通过回购授权，授权总数为96,284,628股，迄今已回购2,666,000股，占当日已发行股份总数约0.2767%。
公司强调，本次股份回购严格遵守香港联合交易所有限公司证券上市规则及相关法例的规定，交易程序亦符合此前于2025年4月29日递交至香港联交所的说明函件所载资料。公告由公司秘书钟明辉签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.